NoGeneST™ Anti-PDGF-B Aptamer, PEG Unconjugated aPDGF-B aptamer-1 sodium

Name: NoGeneST™ Anti-PDGF-B Aptamer, PEG Unconjugated aPDGF-B aptamer-1 sodium
SKU: NRYF-0625-HZ45
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ45]

An PEG40K unconjugated DNA aptamer that inhibits Platelet-derived growth factor B (PDGF-B), a key factor in angiogenesis.

Target:: PDGF-B

Type:: DNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is the core, single-stranded DNA aptamer without the polyethylene glycol (PEG) modification often used to extend in vivo half-life. It is engineered to bind with high affinity and specificity to Platelet-derived growth factor B (PDGF-B), functioning as a direct antagonist. By blocking PDGF-B from interacting with its receptor, it inhibits signaling pathways crucial for pericyte recruitment and maturation during blood vessel formation.

Type

DNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

PDGF-B

Full Name

Platelet-Derived Growth Factor B

Alternative Names

PDGF-2; c-sis

Gene ID

5155

Uniprot ID

P01127

Target Overview

Platelet-Derived Growth Factor B (PDGF-B) is a key member of the PDGF family of growth factors and a potent mitogen for cells of mesenchymal origin. By signaling through its receptor, PDGFRβ, it plays a critical role in angiogenesis (the formation of new blood vessels). Specifically, it is responsible for the recruitment of pericytes, which are mural cells that wrap around and stabilize newly forming vessels. This PDGF-B-mediated signaling pathway is often exploited by tumors to develop a robust blood supply, making it a prime target for anti-angiogenic therapies.

Publications